STRENSIQ
Active substance: asfotase alfa
SOLUTION · ASFOTASE ALFA 18 mg/.45mL
United StatesActive
Marketing holder: Alexion Pharmaceuticals, Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- ASFOTASE ALFA · 18 mg/.45mL
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1208c-4dd3-7b4c-bffe-79ee208f8f9f,01a1208c-4dd5-71a2-9db3-c7c25bf06217,01a1208d-040b-7048-ab85-abc5185d5ef1,01a1209d-0b6d-7896-be79-7af572b58bee;count=4 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 25682-010
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- SUBCUTANEOUS
Sources
- product · openFDA NDC · 25682-010 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 25682-010 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 25682-010 · Verified 2026-10-09 · open in source